• Consensus Rating: Hold
  • Consensus Price Target: $24.85
  • Forecasted Upside: 29.88%
  • Number of Analysts: 16
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$19.13
▼ -0.32 (-1.65%)

This chart shows the closing price for KVUE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kenvue Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KVUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KVUE

Analyst Price Target is $24.85
▲ +29.88% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Kenvue in the last 3 months. The average price target is $24.85, with a high forecast of $30.00 and a low forecast of $18.00. The average price target represents a 29.88% upside from the last price of $19.13.

This chart shows the closing price for KVUE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 16 polled investment analysts is to hold stock in Kenvue. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2024Sanford C. BernsteinInitiated CoverageUnderperform$18.00Low
4/3/2024William BlairInitiated CoverageMarket PerformLow
3/1/2024The Goldman Sachs GroupInitiated CoverageBuy ➝ Neutral$20.00Low
2/9/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$25.00 ➝ $24.00Low
2/9/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$25.00 ➝ $24.00Low
12/19/2023UBS GroupBoost TargetNeutral ➝ Neutral$20.00 ➝ $23.00Low
11/17/2023Piper SandlerInitiated CoverageNeutral$20.00Low
10/10/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$29.00 ➝ $26.00Low
10/4/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$29.00 ➝ $26.00Low
9/11/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$27.00Low
9/7/2023Canaccord Genuity GroupInitiated CoverageBuy$28.00Low
9/7/2023Canaccord Genuity GroupInitiated CoverageBuy$28.00Low
9/6/2023ArgusInitiated CoverageHoldLow
8/24/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$29.00Low
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00Low
7/25/2023Edward JonesInitiated CoverageBuyLow
7/21/2023CitigroupLower TargetNeutral$28.00 ➝ $26.00Low
6/1/2023HSBCInitiated CoverageHold$27.00Low
5/30/2023UBS GroupInitiated CoverageNeutral$28.00Low
5/30/2023BNP ParibasInitiated CoverageNeutral$28.00Low
5/30/2023Royal Bank of CanadaInitiated CoverageOutperform$29.00Low
5/30/2023Bank of AmericaInitiated CoverageBuy$30.00Low
5/30/2023CitigroupInitiated CoverageNeutral$28.00Low
5/30/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$27.00Low
5/30/2023The Goldman Sachs GroupInitiated CoverageNeutral$29.00Low
5/29/2023JPMorgan Chase & Co.Initiated CoverageOverweight$29.00Low
(Data available from 4/14/2019 forward)

News Sentiment Rating

1.03 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/17/2023
  • 16 very positive mentions
  • 27 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
10/17/2023
  • 3 very positive mentions
  • 30 positive mentions
  • 5 negative mentions
  • 8 very negative mentions
11/16/2023
  • 24 very positive mentions
  • 29 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
12/16/2023
  • 31 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/15/2024
  • 29 very positive mentions
  • 20 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
2/14/2024
  • 27 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 23 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 23 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Kenvue logo
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.
Read More

Today's Range

Now: $19.13
Low: $19.12
High: $19.54

50 Day Range

MA: $19.91
Low: $18.83
High: $21.46

52 Week Range

Now: $19.13
Low: $17.82
High: $27.80

Volume

9,414,887 shs

Average Volume

16,139,888 shs

Market Capitalization

$36.63 billion

P/E Ratio

N/A

Dividend Yield

4.18%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kenvue?

The following equities research analysts have issued reports on Kenvue in the last twelve months: Argus, Bank of America Co., BNP Paribas, Canaccord Genuity Group Inc., Citigroup Inc., Deutsche Bank Aktiengesellschaft, Edward Jones, HSBC Holdings plc, JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, The Goldman Sachs Group, Inc., UBS Group AG, and William Blair.
View the latest analyst ratings for KVUE.

What is the current price target for Kenvue?

13 Wall Street analysts have set twelve-month price targets for Kenvue in the last year. Their average twelve-month price target is $24.85, suggesting a possible upside of 29.9%. Bank of America Co. has the highest price target set, predicting KVUE will reach $30.00 in the next twelve months. Sanford C. Bernstein has the lowest price target set, forecasting a price of $18.00 for Kenvue in the next year.
View the latest price targets for KVUE.

What is the current consensus analyst rating for Kenvue?

Kenvue currently has 1 sell rating, 8 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KVUE, but not buy more shares or sell existing shares.
View the latest ratings for KVUE.

What other companies compete with Kenvue?

Other companies that are similar to Kenvue include Coty, Colgate-Palmolive, Ambev, General Mills and Sysco. Learn More about companies similar to Kenvue.

How do I contact Kenvue's investor relations team?

The company's listed phone number is (732) 524-0400. The official website for Kenvue is www.kenvue.com. Learn More about contacing Kenvue investor relations.